FIELD: medicine.
SUBSTANCE: invention refers to medicine and namely to arthrology and deals with prevention and/or treatment of osteoarthritis. For that purpose the composition including 0.4-2.5 mg of calcitonin is injected to the patient perorally in free form or in the form of salt, and delivery agent chosen from the group including N-(5-chlorosalicyloyl)-8-aminocapryl acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2- hydroxybenzoyl]amino)caprylic acid (SNAC) and their monosodium and disodium salts, ethanol solvates and monohydrates of their sodium salts as well as any of their combinations.
EFFECT: calcitonin injected in the above compositions and doses allows creating certain conditions of bioavailability and the peak of its concentration in plasma, which provides decrease of cartilage damage and thus effective treatment and preventive treatment of osteoarthritis.
8 cl, 8 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF CALCITONIN FOR TREATING RHEUMATOID ARTHRITIS | 2006 |
|
RU2453330C2 |
| PHARMACEUTICAL COMPOSITION | 2006 |
|
RU2469709C2 |
| PERORAL INTRODUCTION OF CALCITONIN | 2003 |
|
RU2355417C2 |
| ORAL ADMINISTRATION OF PARATHYROID HORMONE AND CALCITONIN | 2002 |
|
RU2300392C2 |
| CRYSTALLINE FORMS OF DISODIUM SALT OF N-(5-CHLOROSALICILOUL-)-8-AMINOCAPRYLIC ACID | 2006 |
|
RU2507196C2 |
| MIMETIC CALCITONIN FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2689551C1 |
| PEPTIDE ANALOGS FOR TREATMENT OF DISEASES AND DISORDERS | 2012 |
|
RU2616511C2 |
| TREATING DIABETES AND METABOLIC SYNDROME | 2010 |
|
RU2537181C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING HGH FOR ORAL ADMINISTRATION | 2007 |
|
RU2493868C2 |
| 5-CNAC AS AGENT FOR ORAL DELIVERY OF PARATHYROID HORMONE FRAGMENTS | 2002 |
|
RU2322256C2 |
